Coronary disease & ACS

Beta-blocker therapy and angina burden after myocardial infarction: A prespecified substudy of the BETAMI-DANBLOCK trial

Eur Heart J Cardiovasc PharmacotherPublished pre-specified BETAMI-DANBLOCK substudy

Primary result · Angina-related hospital contact/diagnostic ischemia testResult — go to the resultSubdistribution hazard ratio 0.85 95% CI 0.77–0.94

Authors' conclusion

In patients with MI and LVEF≥40%, a moderate dose of beta-blockers was associated with a lower incidence of first angina-related hospital contact/diagnostic ischemia testing, and lower use of calcium-channel blockers. The absence of differences in coronary revascularization, nitrate use and patient-reported angina symptoms suggests that the overall benefit on angina is limited.

Study context

Population
Patients with myocardial infarction (MI) and left ventricular ejection fraction (LVEF)≥40%
Participants
5,574 patients
Comparison
Beta-blockers vs no beta-blockers
  • Beta-blocker groupn = 2,783
  • No beta-blocker groupn = 2,791
Methodological detailsrandomized
  • Randomized

Primary result

As reported in the abstract

Angina-related hospital contact/diagnostic ischemia test · median 3.5 years follow-up

Subdistribution hazard ratio

0.85

95% CI 0.77–0.94

Events by treatment group

Beta-blocker groupvs No beta-blocker group
SHR 0.85 (95% CI 0.77–0.94)

Further findings

OutcomeSHR (95% CI)
Coronary revascularization0.99 (0.76–1.29)
OutcomeBeta-blocker groupNo beta-blocker groupDifference in proportions (percentage points) (95% CI)
Calcium-channel blocker treatmentFewer with beta-blockers22.7%26.6%−3.9 (−6.2 to −1.6)
OutcomeBeta-blocker groupNo beta-blocker groupEstimate
Nitrate useSimilar between groups12.3%12.8%difference in proportions −0.5 (95% CI −2.2 to 1.2)
CCS-score · 12-monthsSimilar between groupsdifference in change −0.04 (95% CI −0.14 to 0.05)

Coronary revascularization

Coronary revascularization occurred in 108 (3.9%) vs. 110 patients (3.9%)

Original publication

Beta-blocker therapy and angina burden after myocardial infarction: A prespecified substudy of the BETAMI-DANBLOCK trial. Eur Heart J Cardiovasc Pharmacother. Published 13 November 2026. doi:10.1093/ehjcvp/pvag097

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.